For years, #RAS and #MYC were considered "undruggable." The success of RAS has changed the conversation. Proud to see this recent @nature.com News & Views highlighting MYC as a promising next frontier and #Peptomyc as a key player helping advance the field. www.nature.com/articles/d41...

Exciting news for patients and for the oncology community. The Phase 3 #daraxonrasib results in mPDAC show once again that pursuing challenging targets can lead to meaningful clinical advances and that ambitious science is worth the effort. nejm.org/doi/full/10.10…#RASiS#MYCiCi

New review just out in Frontiers in Immunology! 🎉 We dive into how #MYC reshapes the tumor–immune interface to drive #immuneescape and resistance to #immunotherapy. Open access here 👉 www.frontiersin.org/journals/imm... @vhio.bsky.social @icreacommunity.bsky.social #peptomyc

We are hiring! If you are interested in joining our Models of Cancer Therapy Laboratory lab at @vhio.bsky.social as a Research Laboratory Technician / Lab Manager, apply here: jobs.vhio.net/en/jobs/7018...

Really happy to share our new open-access review in Frontiers in Cell and Developmental Biology 🎉 #MYC inhibition creates vulnerabilities that can be targeted with #DDR inhibitors. @vhio.bsky.social @icreacommunity.bsky.social #peptomyc @lsouceklab.bsky.social www.frontiersin.org/journals/cel...

Honored to deliver a keynote today at the 19th Scientific Day & 29th Annual Conference of Vall d’Hebron on collaborative, challenge-driven research with transformative health impact. #MYC #OMO-103 #Omomyc @vhio.bsky.social @icreacommunity.bsky.social #peptomyc

Link to the article: www.cell.com/cell-reports...

Huge thanks to Fabio Giuntini, and to the entire teams at @vhio.bsky.social and #peptomyc for making this possible. We also want to acknowledge the support of #AECMM and the @erc.europa.eu for backing research that can make a real difference.

In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.

Our work MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer has been accepted in @cp-cellreports.bsky.social : 🚀

Our news of the week: Poster presented at the first annual @sosclc-aecc.bsky.social Symposium, showcasing the work of Ana Lopez Garza and Hugo Thabussot on #SCLC research, conducted as part of the #AECC 70% Survivorship Challenge. @vhio.bsky.social #peptomyc

Thrilled to share that our senior PhD student Íñigo Gonzalez has presented a poster on MYC inhibition and re-activation of tumor immunity in KRAS-driven NSCLC with diverse mutational profiles in @CellSymposia Cancer-Immunity Cycle. #ImmunoOncology #CancerTreatment #CSCancerImmunity2025

Honored to present our MYC inhibitor research at the Cancer–Immunity Cycle @CellSymposia and connect with leaders in immuno-oncology. Presented by Silvia Casacuberta 👏 #CancerResearch #ImmunoOncology #CancerTreatment #CSCancerImmunity2025

Being normal is overrated. Happy Halloween from the LSoucek lab!

Proud to see our Íñigo González Larreategui presenting a flash talk and poster at #aseicacongress in Bilbao on the therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational landscapes. 👏 @aseica.bsky.social

Intense week for @LSoucekLab! We are happy to see our @dcapi14 presenting a poster on Targeting oncogene cooperation: MYC inhibition enhances response and overcomes resistance to KRAS inhibitors. #TargetingRAS2025 @TargetingRAS Targeting RAS symposium, Salamanca, 2025 👏💪

We are delighted to share that the review “MYC in cancer: from undruggable target to clinical trials” by Jonathan Whitfield and @lsoucek.bsky.social is finally out in Nature Review Drug Discovery. What an amazing journey this has been and still promises to be! rdcu.be/eawOK

@lsoucek.bsky.social is presenting today a seminar at UB regarding the challenge associated to the development of a MYC inhibitor. Info below.